Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice
about
JC virus in the pathogenesis of colorectal cancer, an etiological agent or another component in a multistep process?Regulation of atherogenesis by chemokines and chemokine receptorsEndothelial dysfunction and specific inflammation in obesity hypoventilation syndromeStat3-dependent acute Rantes production in vascular smooth muscle cells modulates inflammation following arterial injury in mice.Induced Pluripotent Stem Cell-Derived Endothelial Cells Overexpressing Interleukin-8 Receptors A/B and/or C-C Chemokine Receptors 2/5 Inhibit Vascular Injury ResponseCalcineurin-mediated YB-1 dephosphorylation regulates CCL5 expression during monocyte differentiation.Regulation of CCL5 expression in smooth muscle cells following arterial injuryChemokines CCL3/MIP1α, CCL5/RANTES and CCL18/PARC are independent risk predictors of short-term mortality in patients with acute coronary syndromes.MCP-1 contributes to arteriovenous fistula failure.Chemokine receptor CCR5: from AIDS to atherosclerosisMyocardin regulates vascular smooth muscle cell inflammatory activation and diseaseDifferential effects of dietary protein sources on postprandial low-grade inflammation after a single high fat meal in obese non-diabetic subjects.Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets.PDGFRβ signalling regulates local inflammation and synergizes with hypercholesterolaemia to promote atherosclerosis.Retinoic acid receptor α mediates all-trans-retinoic acid-induced Klf4 gene expression by regulating Klf4 promoter activity in vascular smooth muscle cells.Y-box binding protein 1 and RNase UK114 mediate monocyte chemoattractant protein 1 mRNA stability in vascular smooth muscle cells.Relationship of Genetic Polymorphisms of the Chemokine, CCL5, and Its Receptor, CCR5, with Coronary Artery Disease in Taiwan.Genetic polymorphisms associated with carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention StudyThe inflammatory preatherosclerotic remodeling induced by intermittent hypoxia is attenuated by RANTES/CCL5 inhibition.Sphingosine kinase 1 regulates tumor necrosis factor-mediated RANTES induction through p38 mitogen-activated protein kinase but independently of nuclear factor κB activation.Chemokines in the vascular inflammatory response of atherosclerosis.Roles of the chemokine system in development of obesity, insulin resistance, and cardiovascular disease.Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases.YB-1: oncoprotein, prognostic marker and therapeutic target?Targeting CCL5 in inflammation.The role of cold shock domain proteins in inflammatory diseases.YB-1 orchestrates onset and resolution of renal inflammation via IL10 gene regulation.YB-1 acts as a ligand for Notch-3 receptors and modulates receptor activation.Expression and network analysis of YBX1 interactors for identification of new drug targets in lung adenocarcinoma.Cold shock proteins: from cellular mechanisms to pathophysiology and disease
P2860
Q24634312-53B7F5F5-94E1-4188-B869-C4D9DB8A5628Q27003124-D5216C60-5E8F-4E0E-801A-758C2E69BF7EQ33496141-C092A92B-E225-4677-8DD0-7577B846D70BQ33559676-3D8F8E79-0DF9-443A-AEF8-250DA5AF7522Q33722663-54A8158E-CC69-4B0D-856D-E08364F4FB24Q33985284-61EC6400-D28A-40D9-AC3F-0ADC9240F2DAQ34146505-91A263B4-D96F-487C-BD88-516E7F389FC5Q34430115-DD1E1E68-5C2D-4F82-BB9C-FAF259FE799EQ34457225-748B1ECC-5D82-467C-8116-FFFC9E317E87Q34672038-E591B542-E17D-480A-8E59-4ABDAF218AC4Q35323782-9995B95F-A05C-41CC-BD0D-A38C38B08D77Q35555437-58694B71-642D-4844-AE5A-BDD4DA83F983Q35640438-534BA18F-E884-44B3-9919-965447F98191Q35865871-0F30AB9C-D392-4954-A18F-1CCB23061146Q35879518-762C1A12-596D-4161-B98C-E79F0267C959Q36197071-FB5CAB62-FD8E-49BA-B368-008537A837A1Q36353087-5EE98445-D3B3-453C-817A-ABF6124500DAQ36537470-1BB891E7-BCE2-4CC5-ACF4-88AA23AA9C1AQ36990311-D336E8CE-2399-4C13-A37E-CC0EC5F32D5BQ37189621-79843BFD-DF51-4A06-AD66-90B1CC23FB9BQ37652971-B7EC5EDA-8F97-43CA-B456-9FBBE552BC1DQ37704741-F2947EA2-1196-4CA3-A087-5CE2BD693D16Q37723178-5EC85BEA-ECFD-4E87-BC26-41F7544FEBEAQ38065264-33A1E92D-169F-4434-B84F-ADA3944771DEQ38148785-20CCF192-314C-4016-B96B-205E7DBBE28FQ38190448-53891F29-9FAC-432A-8178-56814C6F6550Q38700854-600F8FE3-41DD-4537-96FE-1CE324DC83D4Q39819288-D8FFC7D1-B8B7-446A-9B99-AF878DC01A58Q55402211-0AF0920C-E2A3-4AC9-82C2-B9F84058446EQ58695185-0BF5572A-3713-439B-8287-FDE18D2C9412
P2860
Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice
description
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2007
@ast
im Oktober 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2007/10/16)
@sk
vědecký článek publikovaný v roce 2007
@cs
wetenschappelijk artikel (gepubliceerd op 2007/10/16)
@nl
наукова стаття, опублікована в жовтні 2007
@uk
مقالة علمية (نشرت في 16-10-2007)
@ar
name
Y-box binding protein-1 contro ...... in atherosclerosis-prone mice
@ast
Y-box binding protein-1 contro ...... in atherosclerosis-prone mice
@en
Y-box binding protein-1 contro ...... in atherosclerosis-prone mice
@nl
type
label
Y-box binding protein-1 contro ...... in atherosclerosis-prone mice
@ast
Y-box binding protein-1 contro ...... in atherosclerosis-prone mice
@en
Y-box binding protein-1 contro ...... in atherosclerosis-prone mice
@nl
prefLabel
Y-box binding protein-1 contro ...... in atherosclerosis-prone mice
@ast
Y-box binding protein-1 contro ...... in atherosclerosis-prone mice
@en
Y-box binding protein-1 contro ...... in atherosclerosis-prone mice
@nl
P2093
P50
P1433
P1476
Y-box binding protein-1 contro ...... in atherosclerosis-prone mice
@en
P2093
Erik A. Biessen
Peter J. Nelson
Peter J. van Santbrink
Peter R. Mertens
Regina Krohn
P304
P356
10.1161/CIRCULATIONAHA.107.708016
P407
P577
2007-10-16T00:00:00Z